Related Experiment Video

Updated: May 18, 2026

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
09:44

Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis

Published on: October 14, 2025

Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease

Geert D'Haens1, Brian Feagan, Jean-Frédéric Colombel

  • 1Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands. g.dhaens@amc.uva.nl

Gastroenterology
|September 25, 2012
PubMed

Insights

New biologic therapies for inflammatory bowel disease (IBD) show promise but often fail in clinical trials. This review discusses reasons for these failures and suggests improvements for future drug development in IBD.

Area of Science:

  • Gastroenterology
  • Immunology
  • Clinical Pharmacology

Background:

  • Monoclonal antibody therapies have advanced inflammatory bowel disease (IBD) treatment.
  • Tumor necrosis factor (TNF) antagonists are widely used but have limitations, including side effects and waning efficacy.
  • Novel therapeutics are needed as many promising preclinical agents fail in clinical trials.

Purpose of the Study:

  • To identify reasons for the failure of novel IBD therapies in clinical trials.
  • To review regulatory guidelines for clinical trial design and endpoints in IBD.
  • To propose strategies for improving the success rate of future IBD drug development.

Main Methods:

  • Review of existing literature on IBD clinical trials.
  • Analysis of factors contributing to trial failures.
  • Examination of regulatory guidance for therapeutic development.

Main Results:

  • Common reasons for trial failure include high placebo response rates, suboptimal dosing, and inappropriate endpoint timing.
  • The evolving therapeutic landscape and competitive trial environments also impact outcomes.
  • Existing regulatory guidelines may require adaptation for novel IBD therapies.

Conclusions:

  • Improving clinical trial design is crucial for successful IBD drug development.
  • Addressing issues like placebo effects and optimizing trial parameters can enhance efficacy assessment.
  • Strategic adjustments in trial design and regulatory engagement are recommended to improve the success of new IBD treatments.

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease05:08

A TNBS-Induced Rodent Model to Study the Pathogenic Role of Mechanical Stress in Crohn's Disease

Published on: March 1, 2022

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...